Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Down 5.48%
As of Friday, November 20, Odyssey Therapeutics, Inc.’s ODTX share price has dipped by 5.48%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Rosalio Madrigal
Tudor Pop
Jenna Brashear
| Share Statistics | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $808.8 | $203.5 | 44% |
|
| Shares Out (Mil) | 48.0 | 55.2 | 46% |
|
| Institutional Ownership | 95.0% | 93.3% | 66% |
|
| Float (Mil) | 23.7 | 40.4 | 31% |
|
| Beta | na | 1.05 | na |
|
| Avg Daily Volume (000s) | 401 | 569 | 54% |
|
| Price Change (52-week) |
na | 38.8% | na |
|
| Growth | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.7%) | na |
|
| EPS (5yr) | na | 15.4% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($1.030) | ($5.600) | ($4.436) | |
| Month Ago EPS | ($1.006) | ($4.110) | ($4.360) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($1.006) | ($4.255) | ($4.360) | |
| Year/Year Chg | (6.8%) | (88.8%) | (90.6%) | |
| Financials | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($178) | ($44) | 7% |
|
| EPS (TTM) | ($7.956) | ($1.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($142) | ($35) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($74) | $-0 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $18 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $542 | $142 | 36% |
|
| Valuation | ODTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.15 | 1.96 | 61% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (81.1%) | (47.0%) | 7% |
|
| ROE | (94.5%) | (51.8%) | 9% |
|
| Liabilities to Assets | 14.2% | 29.6% | 9% |
|
| F-Score | 1 | 3 | na |
|
Odyssey Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors